

Silco Pharmaceuticals Limited

Un-Audited Financial Statements (Half Yearly)

For the period from 1st July 2024 to 31 December 2024


Silco Pharmaceuticals Limited

Statement of Financial Position

As at December 31, 2024

Particulars	Notes	Amount in Taka	
		31 December 2024	30 June 2024
Assets:			
Non Current Assets		1,772,791,561	1,767,324,096
Property, Plant and Equipment	3.00	1,631,641,217	1,629,983,446
Right of Use Assets	4.00	6,933,397	9,244,529
Capital Work-in-Progress	5.00	134,216,947	128,096,122
Current Assets		1,084,813,917	1,054,936,740
Inventories	6.00	451,065,363	444,095,853
Trade and Other Receivables	7.00	428,050,362	419,594,428
Advances, Deposits and Prepayments	8.00	165,756,380	160,774,234
Cash and Cash Equivalents	9.00	39,941,811	28,699,542
Investment In Share	10.00	-	1,772,684
Total Assets		2,857,605,478	2,822,260,837
Shareholder's Equity and Liabilities:			
Shareholder's Equity		2,381,361,989	2,352,439,767
Share Capital	11.00	1,038,070,000	1,038,070,000
Retained Earnings	12.00	1,343,291,989	1,315,518,064
Unrealized Gain/Loss on Marketable Securities	13.00	-	(1,148,297)
Non-Current Liabilities		158,336,984	159,021,936
Lease Liabilities (Non Current Portion)	14.00	4,184,468	5,308,391
Deferred Tax Liabilities	15.00	154,152,516	153,713,545
Current Liabilities		317,906,505	310,799,133
Trade and Other Payable	16.00	9,425,451	9,604,865
Lease Liabilities (Current Portion)		3,143,222	4,258,996
Payable to IPO Applicants	17.00	184,493	184,493
Provision for Expenses	18.00	5,906,767	6,273,320
Liabilities for contribution to WPPF	19.00	4,676,640	2,906,798
Dividend Payables (Unclaimed)	20.00	1,752,347	2,377,502
Provision for income tax	21.00	292,817,586	285,193,159
Total Shareholder's Equity and Liabilities		2,857,605,478	2,822,260,837
Net Asset Value (NAV) per Share	30.00	22.94	22.66


The annexed notes form an integral part of these financial statements.


Chairman


Managing Director


Director


Company Secretary


Chief Financial Officer

Signed as per our separate report on same date.


Place: Dhaka

Date: 30 January 2025

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income
For the period ended December 31, 2024

Particulars	Notes	Amount in Taka			
		01 July 2024 to 31 Dec. 2024	01 July 2023 to 31 Dec. 2023	01 Oct 2024 to 31 Dec. 2024	01 Oct 2023 to 31 Dec. 2023
Turnover	22.00	226,658,576	207,036,574	111,963,709	104,880,829
Less: Cost of Goods Sold	23.00	152,025,146	134,498,203	78,073,695	68,543,682
Gross Profit/(Loss)		74,633,430	72,538,371	33,890,014	36,337,147
Less: Operating Expenses	24.00	37,043,506	36,173,203	19,732,652	19,249,312
Profit from Operation		37,589,924	36,365,168	14,157,362	17,087,835
Less: Financial Expenses	25.00	49,918	40,155	40,746	31,169
Less: Financial Expenses (Lease)	26.00	373,334	458,956	174,616	267,985
Non-operation Income	27.00	440,492	1,568,911	427,620	556,009
Less: Loss on Sale of Shares		-	5,194,252	-	81,393
Profit before Contribution to WPPF		37,607,163	32,240,715	14,369,620	17,263,296
Less: Workers' Profit Participation/Welfare Fund (WPPF)	19.01	1,769,842	1,460,562	663,905	795,585
Profit before Income Tax		35,837,322	30,780,153	13,705,715	16,467,711
Less: Provision for Income Tax	28.00	8,063,397	7,050,104	3,083,786	3,705,235
Current Tax	28.01	7,624,427	6,759,245	2,686,990	3,366,135
Deferred Tax	28.02	438,970	290,858	396,796	339,100
Net Profit/(Loss) after Tax (Transferred to Retained Earning)		27,773,924	23,730,049	10,621,930	12,762,476
Other Comprehensive Income:					
Unrealized Gain/(Loss) on Investment	13.00		13,702,875		6,876,767
Total Comprehensive income		27,773,924	37,432,924	10,621,930	19,639,243
Earnings per Share (EPS)	29.00	0.27	0.23	0.10	0.12

The annexed notes form an integral part of these financial statements.



Chairman



Managing Director



Director



Company Secretary



Chief Financial Officer

Signed as per our separate report on same date.

Place: Dhaka

Date: 30 January 2025

Silco Pharmaceuticals Limited
Statement of Changes in Equity
For the period ended December 31, 2024






Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2024	1,038,070,000	(1,148,297)	1,315,518,064	2,352,439,767
Net Profit/(Loss) during the period	-	-	27,773,924	27,773,924
Unrealized Gain/(Loss) on Marketable Shares	-	1,148,297		1,148,297
Balance as on Dec. 31, 2024	1,038,070,000	-	1,343,291,989	2,381,361,989

Statement of Changes in Equity
For the period ended December 31, 2023

Amount in Taka

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Total
Balance as at July 01, 2023	1,038,070,000	(6,915,207)	1,288,697,596	2,319,852,389
Net Profit/(Loss) during the period	-	-	23,730,049	23,730,049
Unrealized Gain/Loss on Marketable Shares	-	6,876,767		6,876,767
Balance as on Dec. 31, 2023	1,038,070,000	(38,440)	1,312,427,645	2,350,459,205

 Chairman
 Managing Director
 Director
 Company Secretary
 Chief Financial Officer

Place: Dhaka

Date: 30 January 2025

Silco Pharmaceuticals Limited
Statement of Cash Flows
For the period ended December 31, 2024

Particulars	Notes	Amount in Taka	
		01 July 2024 to 31 Dec. 2024	01 July 2023 to 31 Dec. 2023
A. Cash Flows from Operating Activities			
Cash received from Customers	34.00	218,202,641	164,888,415
Cash received from Non-operating income		1,370,215	1,568,911
Cash Paid to Suppliers	35.00	(98,884,416)	(73,943,786)
Cash Paid to Employees	36.00	(32,661,412)	(31,982,244)
Cash Paid to Others	37.00	(20,347,170)	(20,557,348)
Financial Expenses		(49,918)	(40,155)
Income Tax Paid		(3,021,198)	(1,636,291)
Net cash flows from operating activities		64,608,742	38,297,503
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(630,680)	(46,900)
Cash Payment for Capital Work-in-Progress		(51,488,863)	(20,907,003)
Gain/(Loss) on Investment		(929,723)	(5,194,252)
Investment in Share		2,920,981	25,766,971
Net cash used in investing activities		(50,128,286)	(381,184)
C. Cash Flows from Financing Activities			
Refund to IPO Applicants (Bank Charge)		-	(114)
Financial Expenses (Lease)		(373,334)	(458,956)
Principle payment (Lease)		(2,239,696)	(2,154,074)
Cash dividend paid		(625,156)	(124,549)
Net Cash used for financing activities		(3,238,186)	(2,737,693)
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		11,242,271	35,178,626
E. Cash and Cash Equivalents at the beginning of the year		28,699,542	30,764,262
F. Cash and Cash Equivalents at the end of the period (D+E)		39,941,811	65,942,887
Net Operating Cash Flows Per Share (NOCFPS)	31.00	0.62	0.37

নাইম কাভে
Chairman


Managing Director


Director


Company Secretary


Chief Financial Officer

Place: Dhaka
Date: 30 January 2025